Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis
Status:
Completed
Trial end date:
2020-09-28
Target enrollment:
Participant gender:
Summary
The objective is to evaluate the efficacy and safety of TAK-385 40 mg orally administrated
once daily for 24 weeks compared with Leuprorelin [once/4 weeks, 3.75 or 1.88 mg
subcutaneously (SC)/time] in patients with endometriosis.